Virlogist Kelly Warfield被任命为萨宾疫苗研究所研发主任,重点是马尔堡和苏丹ebola病毒疫苗。 Virologist Kelly Warfield appointed R&D President at Sabin Vaccine Institute, focusing on Marburg and Sudan ebolavirus vaccines.

Kelly Warfield,一位成就卓著的病毒学家和疫苗研制领导人,被任命为萨宾疫苗研究所研究与开发主席。 Kelly Warfield, an accomplished virologist and vaccine development leader, has been appointed as Research & Development President at the Sabin Vaccine Institute. 她将领导研发方案,与董事会和CEO Amy Finan合作,推动本组织的战略愿景。 She will lead the R&D program, working with the Board of Trustees and CEO Amy Finan to drive the organization's strategic vision. Warfield以前在新兴生物解决方案管理了一个300名科学家小组,将重点推动萨宾针对马尔堡和苏丹伊波拉病毒的候选疫苗向通关推进。 Warfield previously managed a 300-scientist team at Emergent BioSolutions and will focus on advancing Sabin's candidate vaccines against Marburg and Sudan ebolavirus towards licensure.